Hospital Británico, Buenos Aires, Argentina.
Hospital A. Oñativia, Salta, Argentina.
Endocrine. 2022 Sep;77(3):493-499. doi: 10.1007/s12020-022-03115-7. Epub 2022 Jul 7.
Non-invasive encapsulated follicular variant of papillary thyroid cancer was reclassified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP). These neoplasms have an extremely low malignant potential. The aim of this study was (1) to assess the prevalence of NIFTP in patients with papillary thyroid carcinoma, (2) to evaluate their outcomes, and (3) to determine their molecular profile.
Multicenter, descriptive, retrospective study. Patients with papillary thyroid cancer diagnosed from January 2006 to December 2016 from 11 referral centers were included. Diagnosis of NIFTP was based on criteria described by Nikiforov et al. in 2018. At least two pathologists agreed on the diagnosis. Two thousand six hundred and seventy-seven papillary thyroid cancer patients were included; 456 (17%) of them were follicular variant papillary thyroid cancer, and 30 (1.12%) fulfilled diagnostic criteria for NIFTP.
Each of the 30 included patients underwent a total thyroidectomy, and 50% were treated with radioiodine (median dose 100 mCi). After a median follow-up of 37 months, 84% of patients had an excellent response, 3% had an indeterminate response and data was missing in the remaining 13%. No metastatic lymph nodes, distant metastases or recurrences were found. RAS mutations were detected in 4 patients (13%).
The prevalence of NIFTP in our series is amongst the lowest reported. Excellent outcomes of patients underscore their low malignant potential. Molecular findings differ from other series, probably related to environmental or ethnic features of our population and the meticulous criteria for diagnosing NIFTP.
非侵袭性包裹滤泡型甲状腺乳头状癌被重新分类为具有滤泡状甲状腺肿瘤伴乳头状核特征的非侵袭性滤泡性肿瘤(NIFTP)。这些肿瘤具有极低的恶性潜能。本研究的目的是:(1)评估 NIFTP 在甲状腺乳头状癌患者中的发生率;(2)评估其结果;(3)确定其分子特征。
多中心、描述性、回顾性研究。纳入了 11 个转诊中心于 2006 年 1 月至 2016 年 12 月期间诊断为甲状腺乳头状癌的患者。NIFTP 的诊断基于 Nikiforov 等人在 2018 年描述的标准。至少两名病理学家同意诊断。共纳入 2677 例甲状腺乳头状癌患者,其中 456 例(17%)为滤泡状变异型甲状腺乳头状癌,30 例(1.12%)符合 NIFTP 的诊断标准。
30 例纳入患者均行全甲状腺切除术,50%的患者接受放射性碘治疗(中位剂量 100 mCi)。中位随访 37 个月后,84%的患者有极好的反应,3%的患者有不确定的反应,其余 13%的数据缺失。未发现转移性淋巴结、远处转移或复发。4 例(13%)患者检测到 RAS 突变。
在我们的系列研究中,NIFTP 的发生率处于报告的最低水平之一。患者的良好预后突出了其低恶性潜能。分子发现与其他系列不同,可能与我们人群的环境或种族特征以及诊断 NIFTP 的细致标准有关。